Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

Also called NCT05540587

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Sung-Hwan Kim (from the registry)
Registry
  • NCT NCT05540587
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05540587. Randomized; no masking; primary purpose treatment. Start 2022-05-20 (actual); primary completion 2024-05-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis
Acronym
ERTEMIS
Condition
Mitral Valve Stenosis
Condition
Stroke
Condition
Systemic Embolism
Intervention (Drug)
Edoxaban
Intervention (Drug)
Warfarin
Lead sponsor
Sung-Hwan Kim (class: other)
Collaborator
Daiichi Sankyo Korea Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05540587
Content hash
c5398ef40b2d9205ea0c07753b083fce4fc9ff4c5ecd93454899d34dbf2fdb67